For our 6th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss what is maintenance therapy and why it would be recommended in advanced NSCLC.
Lung Cancer Video Library - Spanish Language: Video #6 What is maintenance therapy and why would it be recommended in advanced NSCLC?
In this fourteenth video from the Targeted Therapies in Lung Cancer Patient Forum, we present the sixth from the afternoon breakout survivorship sessions, Love, Sex and Cancer, with Dr. Helen Coons.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
- 1 of 3
- View More
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
- 1 of 14
- View More
No Result Found